FDA Approval Activities for this Drug…

Fragmin (dalteparin sodium injection), Pharmacia and Upjohn NDA 20-287/S-31 6/30/03 7/6/03 Fragmin (dalteparin sodium injection), Pharmacia and Upjohn NDA 20-287/S-29 11/19/02 11/22/02 Fragmin (dalteparin sodium injection), Pharmacia and Upjohn NDA 20-287/S-27 11/1/02 11/18/02 Fragmin (dalteparin sodium injection), Pharmacia and Upjohn NDA 20-287/S-21, S-22 & S-23 4/4/02 4/16/02 Fragmin (dalteparin sodium injection), Pharmacia and Upjohn NDA 20-287/S-008 3/30/99 3/31/99 3/31/99 5/18/00 Fragmin Indication: Prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism, in patient undergoing hip replacement surgery. Fragmin (dalteparin sodium injection), Pharmacia and Upjohn NDA 20-287/S-018 8/3/00 8/4/00 8/4/00 Fragmin (dalteparin sodium injection), Pharmacia and Upjohn NDA 20-287/S-011 2/27/03 3/10/03 Fragmin (dalteparin sodium injection), Pharmacia and Upjohn NDA 20-287/S-010 5/25/99 6/19/00 Fragmin Indication: Treatment of unstable angina and non-Q-wave myocardial infarction for the prevention of ischemic complications in patients on concurrent aspirin therapy. Fragmin (dalteparin sodium injection), Pharmacia and Upjohn

For the latest approval information, please locate this drug using this index.